High-dose REGN4461
Phase 2Small molecule
RegeneronHigh-dose REGN4461 is one of 69 small molecule programs targeting Generalized Lipodystrophy. It is currently in Phase 2.
3
Indications
3
Total Trials
0
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
237 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Lucentis
RochePhase 3
Eylea
RegeneronPhase 3
Vabysmo
RochePhase 3
Beovu
NovartisPhase 3
Macugen
PfizerPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Retaane
AAlcon Research
Phase 3
Forzinity
SStealth BioTherapeutics Inc.
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Luye Pharma Conbercept
CChengdu Kanghong Biotech Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Age-Related Macular Degeneration1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for High-dose REGN4461. EMBL-EBI & Wellcome Sanger Institute.
- [4]